Infigratinib: A Game Changer in Urothelial Carcinoma Therapy Bladder 9 Mins Read0 Infigratinib, an FGFR1-3 inhibitor, has shown promise as an adjuvant therapy for invasive urothelial carcinoma. The FDA has approved infigratinib…
Urothelial Carcinoma PROOF 302: A phase III trial of Infigratinib in FGFR3 alterations Bladder 3 Mins Read4 Petros Grivas, MD, PhD, an expert in urothelial carcinoma (UC) research at the University of Washington, has made significant contributions…
